The drug pricing regulator has reduced the retail prices of 543 drugs across 137 non-scheduled cancer drugs, with some cuts exceeding 90% as part of a rationalization of trading margins. read more
The drug pricing regulator has reduced the retail prices of 543 drugs across 137 non-scheduled cancer drugs, with some cuts exceeding 90% as part of a rationalization of trading margins. read more
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in